ArticleFrontiers in immunology2025
Cbl promotes MyD88 ubiquitin-mediated degradation in macrophages via phosphorylation and calcium mobilization.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Precise regulation of Toll-like receptor (TLR) signaling via myeloid differentiation factor 88 (MyD88) is critical for balancing immune defense and inflammation. While ubiquitination represents a dominant mechanism controlling MyD88 stability, the full spectrum of E3 ligases that regulate MyD88 stability remains undefined. Methods: In the present study, we investigated the regulatory role of Cbl in MyD88 signaling in macrophage. Results: We identified Cbl as a direct negative regulator of MyD88 in macrophages. Cbl is upregulated during inflammatory responses, and myeloid-specific Cbl deficiency exacerbates cytokine production and MyD88-dependent signaling in macrophages. Mechanistically, Cbl could interact with MyD88. The overexpression of Cbl promoted the ubiquitination and proteasomal degradation of MyD88, whereas Cbl deficiency abrogated its ubiquitination. Moreover, we found that Cbl activation required intracellular calcium and phosphorylation. Calcium chelation and inhibited phosphorylation of Cbl abrogated Cbl-mediated MyD88 downregulation. Conclusion: findings establish Cbl as a novel suppressor of inflammation and direct-interacting E3 ligase of MyD88 in macrophages. Our study expands the knowledge of intrinsic immunoregulatory networks of TLR- MyD88 signaling and the regulatory mechanism of Cbl, suggesting new therapeutic strategies for inflammatory disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.